top of page


FDA approves Teva's Igalmi for at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder
The FDA has expanded the authorised use of Teva's Igalmi sublingual film to at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder and bipolar disorder, introducing a new outpatient treatment setting.

nuaxia
6 hours ago2 min read


Teva targets $6–7 billion in innovative medicines revenue by 2030 as it outlines expanded R&D strategy
Teva has unveiled an expanded innovative-medicines strategy targeting $6–7 billion in annual revenue by 2030, supported by seven late-stage pipeline assets, potential annual launches and a broader R&D investment programme.

nuaxia
5 days ago2 min read


Teva secures US commercialisation rights to two Samsung Bioepis immunology biosimilars in deal worth up to $420 million
Teva has secured US commercialisation rights to two FDA-approved Samsung Bioepis immunology biosimilars under an agreement worth up to $420 million, expanding its specialty biologics portfolio.

nuaxia
Nov 42 min read


Teva acquires BioXcel neuroscience assets including BXCL501 for up to $125 million
Teva has acquired worldwide rights to BioXcel's BXCL501 neuroscience programme and approved IGALMI product in an asset transaction worth up to $125 million.

nuaxia
Oct 282 min read


Samsung Bioepis and Teva expand biosimilars partnership to up to six candidates
Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates.

nuaxia
Oct 22 min read
bottom of page